Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Colorcon
Harvard Business School
Dow
Johnson and Johnson

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BENICAR HCT

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Benicar Hct

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00122447 ↗ Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance Completed Daiichi Sankyo Inc. N/A 2005-05-01 The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00122447 ↗ Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance Completed Daiichi Sankyo, Inc. N/A 2005-05-01 The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00122447 ↗ Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance Completed National Center for Research Resources (NCRR) N/A 2005-05-01 The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00122447 ↗ Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N/A 2005-05-01 The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Benicar Hct

Condition Name

Condition Name for Benicar Hct
Intervention Trials
Hypertension 5
Healthy 4
Essential Hypertension 2
Healthy Subjects 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Benicar Hct
Intervention Trials
Hypertension 7
Essential Hypertension 2
Glucose Intolerance 1
Overweight 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Benicar Hct

Trials by Country

Trials by Country for Benicar Hct
Location Trials
United States 118
Mexico 5
Chile 4
China 2
Japan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Benicar Hct
Location Trials
New York 5
California 5
North Dakota 5
Florida 5
Indiana 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Benicar Hct

Clinical Trial Phase

Clinical Trial Phase for Benicar Hct
Clinical Trial Phase Trials
Phase 4 5
Phase 3 3
Phase 2 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Benicar Hct
Clinical Trial Phase Trials
Completed 15
Not yet recruiting 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Benicar Hct

Sponsor Name

Sponsor Name for Benicar Hct
Sponsor Trials
Daiichi Sankyo Inc. 4
Daiichi Sankyo, Inc. 4
Mylan Pharmaceuticals 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Benicar Hct
Sponsor Trials
Industry 18
Other 4
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Moodys
Dow
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.